Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Yuhan Corporation
Yuhan makes and sells medicines, from prescription drugs to everyday remedies, along with the ingredients and chemicals used to produce them.
Yuhan is one of South Korea's oldest drugmakers, and its business is easy to picture: it develops and sells medicines. That includes prescription drugs that doctors order for serious conditions, over-the-counter remedies people buy on their own, and the active ingredients and chemicals that go into making medicines. It sells these in South Korea and abroad.
The company is best known for a few blockbuster products. Its biggest is Leclaza, a lung cancer pill that has become a major growth driver and won approvals beyond Korea. Yuhan also sells treatments for chronic conditions and a long-standing portfolio of consumer health products, which gives it steady everyday sales alongside the bigger swings of prescription medicine. It makes money when hospitals, pharmacies, and distributors buy its drugs, and when consumers pick up its over-the-counter products. What makes Yuhan interesting is that it doesn't just sell other companies' molecules. It does its own research and development, and it has struck licensing deals with global partners that pay it upfront and milestone payments for promising drugs. That is a risky but potentially lucrative bet: a single successful drug can be worth many years of ordinary sales. Yuhan is headquartered in Seoul and is listed on the Korea Exchange.
Like most drugmakers, its fortunes depend on getting new medicines approved, keeping patents protected, and handling price pressure from Korea's health system. It competes with much larger global pharmaceutical companies and with other Korean drugmakers. The core question for investors is simple: can Yuhan keep turning its research pipeline into approved, selling drugs, and can Leclaza keep growing as it expands into more markets?
Saved answer · last researched 12 Nov 2026